| 摘要 |
The present invention is related to enhancing the function of anti-tumor antibodies by regulating Fc gamma RIIB-mediated activity. In particular, disrupting SHIP activation by Fc gamma RIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The invention further provides an antibody, e.g., an anti-tumor antibody, with a variant Fc region that results in binding of the antibody to Fc gamma RIIB with reduced affinity. A variety of transgenic mouse models demonstrate that the inhibiting Fc gamma RIIB molecule is a potent regulator of cytotoxicity in vivo. |
